Multiobjective strategies for New Product Development in the pharmaceutical industry

New Product Development (NPD) constitutes a challenging problem in the pharmaceutical industry, due to the characteristics of the development pipeline. Formally, the NPD problem can be stated as follows: select a set of R&D projects from a pool of candidate projects in order to satisfy several criteria (economic profitability, time to market) while coping with the uncertain nature of the projects. More precisely, the recurrent key issues are to determine the projects to develop once target molecules have been identified, their order and the level of resources to assign. In this context, the proposed approach combines discrete event stochastic simulation (Monte Carlo approach) with multiobjective genetic algorithms (NSGAII type, Non-Sorted Genetic Algorithm II) to optimize the highly combinatorial portfolio management problem. In that context, Genetic Algorithms (GAs) are particularly attractive for treating this kind of problem, due to their ability to directly lead to the so-called Pareto front and to account for the combinatorial aspect. This work is illustrated with a study case involving nine interdependent new product candidates targeting three diseases. An analysis is performed for this test bench on the different pairs of criteria both for the bi- and tricriteria optimization: large portfolios cause resource queues and delays time to launch and are eliminated by the bi- and tricriteria optimization strategy. The optimization strategy is thus interesting to detect the sequence candidates. Time is an important criterion to consider simultaneously with NPV and risk criteria. The order in which drugs are released in the pipeline is of great importance as with scheduling problems

Multiobjective strategies for New Product Development in the pharmaceutical industry

New Product Development (NPD) constitutes a challenging problem in the pharmaceutical industry, due to the characteristics of the development pipeline. Formally, the NPD problem can be stated as follows: select a set of R&D projects from a pool of candidate projects in order to satisfy several criteria (economic profitability, time to market) while coping with the uncertain nature of the projects. More precisely, the recurrent key issues are to determine the projects to develop once target molecules have been identified, their order and the level of resources to assign. In this context, the proposed approach combines discrete event stochastic simulation (Monte Carlo approach) with multiobjective genetic algorithms (NSGAII type, Non-Sorted Genetic Algorithm II) to optimize the highly combinatorial portfolio management problem. In that context, Genetic Algorithms (GAs) are particularly attractive for treating this kind of problem, due to their ability to directly lead to the so-called Pareto front and to account for the combinatorial aspect. This work is illustrated with a study case involving nine interdependent new product candidates targeting three diseases. An analysis is performed for this test bench on the different pairs of criteria both for the bi- and tricriteria optimization: large portfolios cause resource queues and delays time to launch and are eliminated by the bi- and tricriteria optimization strategy. The optimization strategy is thus interesting to detect the sequence candidates. Time is an important criterion to consider simultaneously with NPV and risk criteria. The order in which drugs are released in the pipeline is of great importance as with scheduling problems

04461 Abstracts Collection -- Practical Approaches to Multi-Objective Optimization

From 07.11.04 to 12.11.04, the Dagstuhl Seminar 04461 ``Practical Approaches to Multi-Objective Optimization\u27\u27 was held in the International Conference and Research Center (IBFI), Schloss Dagstuhl. During the seminar, several participants presented their current research, and ongoing work and open problems were discussed. Abstracts of the presentations given during the seminar as well as abstracts of seminar results and ideas are put together in this paper. The first section describes the seminar topics and goals in general. Links to extended abstracts or full papers are provided, if available

On multimodality of obnoxious faclity location models

Obnoxious single facility location models are models that have the aim to find the best location for an undesired facility. Undesired is usually expressed in relation to the so-called demand points that represent locations hindered by the facility. Because obnoxious facility location models as a rule are multimodal, the standard techniques of convex analysis used for locating desirable facilities in the plane may be trapped in local optima instead of the desired global optimum. It is assumed that having more optima coincides with being harder to solve. In this thesis the multimodality of obnoxious single facility location models is investigated in order to know which models are challenging problems in facility location problems and which are suitable for site selection. Selected for this are the obnoxious facility models that appear to be most important in literature. These are the maximin model, that maximizes the minimum distance from demand point to the obnoxious facility, the maxisum model, that maximizes the sum of distance from the demand points to the facility and the minisum model, that minimizes the sum of damage of the facility to the demand points. All models are measured with the Euclidean distances and some models also with the rectilinear distance metric. Furthermore a suitable algorithm is selected for testing multimodality. Of the tested algorithms in this thesis, Multistart is most appropriate. A small numerical experiment shows that Maximin models have on average the most optima, of which the model locating an obnoxious linesegment has the most. Maximin models have few optima and are thus not very hard to solve. From the Minisum models, the models that have the most optima are models that take wind into account. In general can be said that the generic models have less optima than the weighted versions. Models that are measured with the rectilinear norm do have more solutions than the same models measured with the Euclidean norm. This can be explained for the maximin models in the numerical example because the shape of the norm coincides with a bound of the feasible area, so not all solutions are different optima. The difference found in number of optima of the Maxisum and Minisum can not be explained by this phenomenon

The 1st International Electronic Conference on Algorithms

This book presents 22 of the accepted presentations at the 1st International Electronic Conference on Algorithms which was held completely online from September 27 to October 10, 2021. It contains 16 proceeding papers as well as 6 extended abstracts. The works presented in the book cover a wide range of fields dealing with the development of algorithms. Many of contributions are related to machine learning, in particular deep learning. Another main focus among the contributions is on problems dealing with graphs and networks, e.g., in connection with evacuation planning problems

Cooperation in self-organized heterogeneous swarms

Cooperation in self-organized heterogeneous swarms is a phenomenon from nature with many applications in autonomous robots. I specifically analyzed the problem of auto-regulated team formation in multi-agent systems and several strategies to learn socially how to make multi-objective decisions. To this end I proposed new multi-objective ranking relations and analyzed their properties theoretically and within multi-objective metaheuristics. The results showed that simple decision mechanism suffice to build effective teams of heterogeneous agents and that diversity in groups is not a problem but can increase the efficiency of multi-agent systems

Particle Swarm Optimization

Particle swarm optimization (PSO) is a population based stochastic optimization technique influenced by the social behavior of bird flocking or fish schooling.PSO shares many similarities with evolutionary computation techniques such as Genetic Algorithms (GA). The system is initialized with a population of random solutions and searches for optima by updating generations. However, unlike GA, PSO has no evolution operators such as crossover and mutation. In PSO, the potential solutions, called particles, fly through the problem space by following the current optimum particles. This book represents the contributions of the top researchers in this field and will serve as a valuable tool for professionals in this interdisciplinary field

Journal of Telecommunications and Information Technology, 2010, nr 3

kwartalni

Optimisation du développement de nouveaux produits dans l'industrie pharmaceutique par algorithme génétique multicritère

Le développement de nouveaux produits constitue une priorité stratégique de l'industrie pharmaceutique, en raison de la présence d'incertitudes, de la lourdeur des investissements mis en jeu, de l'interdépendance entre projets, de la disponibilité limitée des ressources, du nombre très élevé de décisions impliquées dû à la longueur des processus (de l'ordre d'une dizaine d'années) et de la nature combinatoire du problème. Formellement, le problème se pose ainsi : sélectionner des projets de Ret D parmi des projets candidats pour satisfaire plusieurs critères (rentabilité économique, temps de mise sur le marché) tout en considérant leur nature incertaine. Plus précisément, les points clés récurrents sont relatifs à la détermination des projets à développer une fois que les molécules cibles sont identifiées, leur ordre de traitement et le niveau de ressources à affecter. Dans ce contexte, une approche basée sur le couplage entre un simulateur à événements discrets stochastique (approche Monte Carlo) pour représenter la dynamique du système et un algorithme d'optimisation multicritère (de type NSGA II) pour choisir les produits est proposée. Un modèle par objets développé précédemment pour la conception et l'ordonnancement d'ateliers discontinus, de réutilisation aisée tant par les aspects de structure que de logique de fonctionnement, a été étendu pour intégrer le cas de la gestion de nouveaux produits. Deux cas d'étude illustrent et valident l'approche. Les résultats de simulation ont mis en évidence l'intérêt de trois critères d'évaluation de performance pour l'aide à la décision : le bénéfice actualisé d'une séquence, le risque associé et le temps de mise sur le marché. Ils ont été utilisés dans la formulation multiobjectif du problème d'optimisation. Dans ce contexte, des algorithmes génétiques sont particulièrement intéressants en raison de leur capacité à conduire directement au front de Pareto et à traiter l'aspect combinatoire. La variante NSGA II a été adaptée au problème pour prendre en compte à la fois le nombre et l'ordre de lancement des produits dans une séquence. A partir d'une analyse bicritère réalisée pour un cas d'étude représentatif sur différentes paires de critères pour l'optimisation bi- et tri-critère, la stratégie d'optimisation s'avère efficace et particulièrement élitiste pour détecter les séquences à considérer par le décideur. Seules quelques séquences sont détectées. Parmi elles, les portefeuilles à nombre élevé de produits provoquent des attentes et des retards au lancement ; ils sont éliminés par la stratégie d'optimistaion bicritère. Les petits portefeuilles qui réduisent les files d'attente et le temps de lancement sont ainsi préférés. Le temps se révèle un critère important à optimiser simultanément, mettant en évidence tout l'intérêt d'une optimisation tricritère. Enfin, l'ordre de lancement des produits est une variable majeure comme pour les problèmes d'ordonnancement d'atelier. ABSTRACT : New Product Development (NPD) constitutes a challenging problem in the pharmaceutical industry, due to the characteristics of the development pipeline, namely, the presence of uncertainty, the high level of the involved capital costs, the interdependency between projects, the limited availability of resources, the overwhelming number of decisions due to the length of the time horizon (about 10 years) and the combinatorial nature of a portfolio. Formally, the NPD problem can be stated as follows: select a set of R and D projects from a pool of candidate projects in order to satisfy several criteria (economic profitability, time to market) while copying with the uncertain nature of the projects. More precisely, the recurrent key issues are to determine the projects to develop once target molecules have been identified, their order and the level of resources to assign. In this context, the proposed approach combines discrete event stochastic simulation (Monte Carlo approach) with multiobjective genetic algorithms (NSGA II type, Non-Sorted Genetic Algorithm II) to optimize the highly combinatorial portfolio management problem. An object-oriented model previously developed for batch plant scheduling and design is then extended to embed the case of new product management, which is particularly adequate for reuse of both structure and logic. Two case studies illustrate and validate the approach. From this simulation study, three performance evaluation criteria must be considered for decision making: the Net Present Value (NPV) of a sequence, its associated risk defined as the number of positive occurrences of NPV among the samples and the time to market. Theyv have been used in the multiobjective optimization formulation of the problem. In that context, Genetic Algorithms (GAs) are particularly attractive for treating this kind of problem, due to their ability to directly lead to the so-called Pareto front and to account for the combinatorial aspect. NSGA II has been adapted to the treated case for taking into account both the number of products in a sequence and the drug release order. From an analysis performed for a representative case study on the different pairs of criteria both for the bi- and tricriteria optimization, the optimization strategy turns out to be efficient and particularly elitist to detect the sequences which can be considered by the decision makers. Only a few sequences are detected. Among theses sequences, large portfolios cause resource queues and delays time to launch and are eliminated by the bicriteria optimization strategy. Small portfolio reduces queuing and time to launch appear as good candidates. The optimization strategy is interesting to detect the sequence candidates. Time is an important criterion to consider simultaneously with NPV and risk criteria. The order in which drugs are released in the pipeline is of great importance as with scheduling problems

A metaheuristic-based framework for index tracking with practical constraints

Recently, numerous investors have shifted from active strategies to passive strategies because the passive strategy approach affords stable returns over the long term. Index tracking is a popular passive strategy. Over the preceding year, most researchers handled this problem via a two-step procedure. However, such a method is a suboptimal global-local optimization technique that frequently results in uncertainty and poor performance. This paper introduces a framework to address the comprehensive index tracking problem (IPT) with a joint approach based on metaheuristics. The purpose of this approach is to globally optimize this problem, where optimization is measured by the tracking error and excess return. Sparsity, weights, assets under management, transaction fees, the full share restriction, and investment risk diversification are considered in this problem. However, these restrictions increase the complexity of the problem and make it a nondeterministic polynomial-time-hard problem. Metaheuristics compose the principal process of the proposed framework, as they balance a desirable tradeoff between the computational resource utilization and the quality of the obtained solution. This framework enables the constructed model to fit future data and facilitates the application of various metaheuristics. Competitive results are achieved by the proposed metaheuristic-based framework in the presented simulation